Incurable astrocytomas, including the particularly malignant glioblastomas, diffusively grow like mycelium into healthy brain tissue.
Therefore, these tumours cannot be completely removed by surgery and invariably start growing again at some point despite intensive treatment.
They appear to have effective resistance mechanisms.
In their latest publication, scientists co-working with Frank Winkler from the Clinical Cooperation Unit (CCU) "Neurooncology" of the DKFZ and Heidelberg University Hospital, describe a striking feature of astrocytoma cells: They form extremely thin and long extensions of their cellular membrane, which they use to constantly scan the healthy brain, thus invading and colonising it.
As the tumour grows, the cancer cells use these extensions to interconnect to a large network where they communicate intensively and via long distances, making astrocytomas appear like highly complex, organ-like entities.
"Our first thought was: this looks like the formation of a new brain within the existing one," Winkler said.
"The tumour cells were interconnected in a network that resembles the ones we know of neurons and other cell types in the brain."
For up to one year, the researchers observed the growth of human glioblastoma cells that they had transferred to mice.
They used a special microscopy technique that facilitates insights into the brain's deep zones.
In this way, they discovered that the cancer cells exchanged molecules via their membrane microtubes which they also used as communication channels.
The investigators also found this network of tumour microtubes in tissue samples from brain cancer patients.
The more the cancer cells were interconnected, the more malignant and resistant the tumour subtype was.
The scientists therefore hypothesised that the tumour microtube networks must be linked to therapy resistance.
They observed that the tumours in fact recognise damage to the network and repair it immediately.
Radiation therapy - the standard treatment in glioblastoma - fails to kill mainly the tumour cells that are part of the network, whereas cancer cells outside the network die.
How do the tumour cells form these extraordinary membrane extensions?
An analysis of the gene activities in tumour tissue from 250 brain cancer patients provided a clue.
For building their network, the cancer cells make use of specific molecular signalling pathways that are normally active during early development of the nervous system.
Experiments in which the scientists blocked these pathways in mice showed that the animals subsequently developed smaller tumours with fewer interconnections that responded very sensitively to radiotherapy.
"The resistance of astrocytomas, particularly glioblastomas, against all types of therapy is an enormous problem," says Wolfgang Wick, who heads the CCU as well as the Neurology Department of Heidelberg University Hospital.
"For the first time, our results show a long sought-after new approach toward breaking this resistance and thus enabling us eventually to enhance the treatment efficacies of these tumours. The results also explain why a specific subtype of brain cancer responds much better to therapy. Their capability of building networks seems to be limited."
Matthias Osswald, the article's first author, adds: "Even though this discovery does not immediately enable us to offer a new treatment to our brain tumour patients, it does show the direction that therapy development should take: we have to destroy the malignant network."
Reference
Osswald, Jung, Sahm et al. (2015) Malignant network makes brain cancer resistant, Nature
Source: German Cancer Research Center